Scinai Immunotherapeutics Ltd. (SCNI) is a Jerusalem-based biopharmaceutical company that operates a contract development and manufacturing organization (CDMO) serving drug developers, alongside an early-stage immunology platform built on NanoAb antibody technology. Its Nasdaq-listed American Depositary Shares were trading at $0.3107 late Wednesday morning, a decline of 16.22% from the previous session's close of $0.371. The direction is unambiguously lower, and the move extends a bruising stretch that has left the ADSs more than 90% below where they began 2026. The immediate driver is a corporate action rather than an operating development: the company's announced change to its ADS-to-ordinary-share ratio, which functions as a one-for-four reverse split, takes effect before Thursday's open.
On Nov. 17, Scinai disclosed that effective Nov. 19 the ratio of ADSs to non-traded ordinary shares will move from 1 ADS representing 40,000 ordinary shares to 1 ADS representing 160,000 ordinary shares. For ADS holders, that is economically identical to a one-for-four reverse split. The stated objective is to lift the per-ADS trading price and regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a $1.00 minimum bid on the Capital Market.
The arithmetic works on paper — a fourfold uplift from roughly $0.31 would put the adjusted price above $1.00 — but the market treated the announcement as a warning rather than a fix. Reverse splits do not alter intrinsic value, and in micro-caps they are frequently read as confirmation that the underlying business cannot support the share price organically. The ADSs already slipped 7.82% on the announcement session, and Wednesday's session represents a second wave of selling as holders position ahead of the adjustment.
What amplifies the reaction is the pattern. Scinai completed a one-for-ten ADS ratio change effective Aug. 21, 2026, for the same stated purpose of curing a minimum bid-price deficiency. A second consolidation less than three months later suggests the first did not hold, and it lands alongside an active funding program: a roughly $4.0 million private placement and warrant inducement that closed Oct. 16, about $1.67 million in net proceeds under a standby equity purchase agreement, and a resale registration covering newly issued shares. Each of those mechanisms expands the share count, and the resulting supply overhang competes directly with any recovery in the quoted price. The company is, in effect, trying to fix a price problem while simultaneously adding paper.
The operating story is not the problem. Nine-month revenue through Sept. 30 rose 167% to $2.8 million, committed customer orders reached $8.32 million by early November, and an expanded U.S. customer program added roughly $5.1 million in committed base services. Management has guided to a cash runway into late 2027, potentially extending toward the third quarter of 2028 if additional manufacturing scope is activated. Against that, the enlarged CDMO cost base produced a $2.97 million gross loss and a $6.56 million operating loss, and the narrower $0.39 million net loss owed almost entirely to a $6.40 million non-cash bargain purchase gain from the Recipharm Israel acquisition. Those figures were published Nov. 5 and have already been absorbed; they are context, not the trigger for Wednesday's decline.
Volume was clearly elevated, with roughly 374,000 ADSs changing hands by late morning against 67,735 for the entire prior session and 28,919 the session before. Recent weeks have typically seen turnover between 30,000 and 100,000 ADSs, so the pace of trading ran several times normal. The selling was idiosyncratic rather than sector-driven: no peer or broad biotech catalyst was identified, and the move was concentrated in this single micro-cap name with a market value near $1 million.
Technically, the damage is severe. The intraday low of $0.2866 broke below the prior 52-week floor around $0.39 and left the shares far beneath both their 20-day and 200-day moving averages. With a float this thin, order books are shallow and modest sell programs can move the quote by double digits.
The scale runs from 0 — no meaningful news and a move that is ordinary for the stock — to 100, meaning transformative news paired with an extreme, rare price move. The score here is 36 out of 100.
The verified news is a listing-compliance and capital-structure action: a one-for-four reverse split, the second in three months, at a company valued near $1 million. That is material to the share structure but not to the business itself, so the catalyst ranks as moderate. The price move was meaningful but not exceptional by this stock's own standards — roughly 2.4 times its typical daily swing, yet matched or exceeded in seven of the past 60 sessions. Strong volume supports the higher end of that range, but the stock's habit of double-digit swings caps the anomaly component. Moderate news plus a large-but-routine move combine into a mid-range score.
Thursday's split-adjusted open is the first test: the ADSs will quote near four times Wednesday's level, and the key question is whether the bid holds above $1.00 long enough to satisfy Nasdaq's compliance window. On the operating side, investors will focus on how quickly the $8.32 million order book converts to revenue and cash, whether the expanded U.S. customer agreement activates its uncommitted later phases, and how long the roughly $8 million in reported bank balances lasts against a still-negative gross margin. The next quarterly report and any further capital raises are the obvious near-term risk points, alongside the possibility of additional registered supply hitting the market. There is no assurance the ratio change will restore compliance, and the company has said as much.
Tickeron's Trending AI Robots page curates the strongest-performing automated strategies under current market conditions, drawn from a library of hundreds of AI trading bots spanning thousands of tickers. The bots differ widely by strategy logic, holding timeframe, performance metrics, and the symbols they trade, so the featured list rotates as conditions change. For traders who want to see which automated approaches are working right now — rather than guess — this is a practical starting point to review and compare live performance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SCNI declined for three days, in 310 of 340 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for SCNI entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +10.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where SCNI advanced for three days, in 149 of 197 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
SCNI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.049) is normal, around the industry mean (3.592). P/E Ratio (0.016) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.536) is also within normal values, averaging (442.120).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. SCNI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SCNI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of the innovative flu vaccine
Industry Biotechnology